Abstract:Purpose: Fibrin glue (FG) has been used as a delivery system for bioactive agents on grafts and angioplasty sites. Reports from two different institutions suggest that heparin concentrations of 500 U/mL in FG inhibit smooth muscle cell (SMC) proliferation, but do not effect endothelial cell (EC) proliferation. The purposes of this study were to (1) quantify the diffusive release of fibroblast growth factor-1 (FGF-1) and heparin from FG; (2) determine the effect of heparin and FGF-1 on SMC proliferation when the cells are immediately plated on the FG; and (3) by means of the diffusive release data, design a new in vitro model that may differentiate the effect of FG-incorporated FGF-1 and heparin, rather than the released, solubilized components of these two factors, on SMC and EC proliferation. Methods: 125I-FGF-1 or 3H-heparin release from FG into the overlying media was measured serially in a 96-hour period, either with or without cells. SMCs were immediately plated on FG containing various concentrations of FGF-1 and heparin. SMCs or ECs were plated on identical groups of FG containing FGF-1 and heparin 24 hours after the FG was made to exclude the effect on cell growth of the initial release of FGF-1 into the media. Results: In the first 24 hours, 70% +/- 1% of the FGF-1 and 59% +/- 2% of the heparin in the FG was released into the overlying media, with minimal release occurring thereafter. The cell type or absence of cells did not affect release, but there was five times more FGF-1 and four times more heparin in the media at 72 hours for the immediate plating versus the delayed plating because of a diffusive release primarily in the first 24 hours. A heparin concentration of 500 U/mL inhibited SMC proliferation, as compared with 5 U/mL heparin, only when immediate plating of SMCs was used. Comparing immediate versus delayed SMC plating, at equivalent FGF-1 and heparin doses, immediate plating induced greater proliferation than delayed plating; this was likely caused by the higher soluble FGF-1 concentration. Heparin doses as high as 500 U/mL had little effect on SMC proliferation. In contrast, ECs died with delayed plating on FG containing 500 U/mL heparin, and their growth was inhibited at 50 U/mL heparin, as compared with 5 U/mL heparin. Conclusion: The differences in SMC proliferation when comparing immediate versus delayed plating are likely caused by diffusive release of heparin and FGF-1 into the media. Our ongoing work uses an optimized in vitro FG system that minimizes the effects of soluble factors. This is an important distinction, because the cytokines that are released in vivo will be removed by blood flow and, thus, may not exert an effect unless they are contained within the FG.

[Effects of Placental Growth Factor on the Secretion of Proinflammatory Cytochemokines in Vascular Endothelial Cells].

[Effect of Lipopolysaccharide of Porphyromonas Gingivalis on Prostaglandin E2 Biosynthetic Pathway in Human Monocytic Cell Strain THP-1].

Placental Growth Factor Expression is Reversed by Antivascular Endothelial Growth Factor Therapy under Hypoxic Conditions

[Effects of Porphyromonas Gingivalis on Inflammatory Factor Secreted by Human Umbilical Vein Endothelial Cells].

Expression of Placental Vascular Growth Factor in Pregnancy-Induced Hypertension

Effect of Porphyromonas gingivalis lipopolysaccharide on induced secretion of inflammatory cytokines by different cell lines]

[Effects of Advanced Glycation End Products on the Secretion of Proinflammatory Chemokines in Vascular Smooth Muscle Cells].

Inhibitory Effects of Eicosapentaenoic Acid on Vascular Endothelial Growth Factor-Induced Monocyte Chemoattractant Protein-1, Interleukin-6, and Interleukin-8 in Human Vascular Endothelial Cells

Placental growth factor mediates pathological uterine angiogenesis by activating the NFAT5-SGK1 signaling axis in the endometrium: implications for preeclampsia development

Effects of Platelet-derived Membrane Microparticles on the Proliferation and Apoptosis of Human Umbilical Vein Endothelial Cells

[Adhesion between monocytes and vascular smooth muscle cells induced by integrin beta1-mediated platelet-derived growth factor].

Placenta Growth Factor-1 Exerts Time-Dependent Stabilization of Adherens Junctions Following VEGF-Induced Vascular Permeability

Placental Growth Factor Promotes Epithelial-Mesenchymal Transition-Like Changes in ARPE-19 Cells under Hypoxia.

Inhibitory Effect on Subretinal Fibrosis by Anti-Placental Growth Factor Treatment in a Laser-Induced Choroidal Neovascularization Model in Mice.

Effect of PPARα Ligands on Secretion of Inflammatory Cytokines in Foam Cells

Effects of A Thrombomodulin-Derived Peptide on Monocyte Adhesion and Intercellular Adhesion Molecule-1 Expression in Lipopolysaccharide-Induced Endothelial Cells

Engineered endothelial progenitor cells that overexpress prostacyclin protect vascular cells.

Effects of eicosapentaenoic acid on inflammatory cytokine secretion in endothelial cells stimulated by lipopolysaccharide

Vascular endothelial growth factor signaling implicated in neuroprotective effects of placental growth factor in an in vitro ischemic model.

Modulation of vascular cell growth kinetics by local cytokine delivery from fibrin glue suspensions

The Potential for Placental Activation of PPARγ to Improve the Angiogenic Profile in Preeclampsia